SCHEMBL7140975

SCHEMBL7140975

COc1ccc(CSC2CC(CCC(=O)N(C)Cc3ccccc3)N(S(=O)(=O)c3ccc4ccccc4c3)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 6/20 0.44
MMP13 P45452 6/20 0.44
MMP3 P08254 5/20 0.44
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPK1 P28482 1/20 0.39
MMP9 P14780 4/20 0.38
MMP2 P08253 3/20 0.38
MMP7 P09237 2/20 0.38
CCR4 P51679 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
MME P08473 1/20 0.37
ACE P12821 1/20 0.37
ECE1 P42892 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135066 1.00 MMP1 (0.44) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL5406027 0.90 ALDH1A1 (0.44) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL5406020 0.90 ALDH1A1 (0.44) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL7134640 0.89 LMNA (0.47) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL7144857 0.89 LMNA (0.47) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL7151570 0.86 ALDH1A1 (0.47) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL7135171 0.86 ALDH1A1 (0.47) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL5415820 0.83 ALDH1A1 (0.46) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL5415835 0.83 ALDH1A1 (0.46) MMP1MMP13MMP3ALDH1A1LMNA
SCHEMBL5405036 0.82 ALDH1A1 (0.43) MMP1MMP13MMP3ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MMP1 48/4885MMP13 96/4885MMP3 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.